Alumis Inc./$ALMS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alumis Inc.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
- Ticker
- $ALMS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 238
- Headquarters
- South San Francisco, United States
- Website
- www.alumis.com
Alumis Inc. Metrics
BasicAdvanced
$871M
-
-$3.80
-0.67
-
Price and volume
Market cap
$871M
Beta
-0.67
52-week high
$31.35
52-week low
$4.39
Average daily volume
2.1M
Financial strength
Current ratio
6.744
Quick ratio
6.64
Long term debt to equity
0.07
Total debt to equity
0.081
Profitability
EBITDA (TTM)
-421.449
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-5,933.45%
Operating margin (TTM)
-5,744.48%
Effective tax rate (TTM)
0.40%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-45.34%
Return on equity (TTM)
-93.65%
Valuation
Price to revenue (TTM)
105.071
Price to book
1.91
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
-2.21
Free cash flow yield (TTM)
-45.26%
Free cash flow per share (TTM)
-3.046
Growth
Revenue change (TTM)
-63.11%
Earnings per share change (TTM)
-0.13%
What the Analysts think about Alumis Inc.
Analyst ratings (Buy, Hold, Sell) for Alumis Inc. stock.
Analyst projections of the future price of Alumis Inc. stock.
Bulls say / Bears say
In ONWARD3, 54% of patients achieved complete skin clearance at 48 weeks and 75% reached PASI 90; Alumis reported no new long-term safety signals. The results support envudeucitinib’s psoriasis case ahead of a planned FDA filing in the fourth quarter of 2026. (Alumis)
Although the overall lupus trial missed its endpoints, a prespecified subgroup with high interferon activity showed strong improvement, including on the main disease-activity measure. That result may support a biomarker-selected Phase 3 programme, subject to discussions with regulators. (Reuters)
Alumis reported $502.3 million in cash, cash equivalents and marketable securities at the end of June, which it expects to fund operations and capital spending into the fourth quarter of 2027. That provides time to pursue its psoriasis filing and planned development work without an immediate funding need. (Alumis)
Envudeucitinib failed to meet the primary and secondary endpoints in the overall Phase 2b lupus population. The positive interferon-high subgroup result remains uncertain and would need to underpin a new trial design and be confirmed in later-stage testing. (Reuters)
Envudeucitinib would enter a crowded psoriasis-pill market that includes established and newly approved rivals. Analysts have questioned whether its twice-daily dosing and efficacy will offer enough differentiation, although the comparisons are not from head-to-head trials. (Clinical Trials Arena)
Alumis used $168.6 million in operating cash in the first half of 2026 and continues to report substantial losses. Its stated runway only extends into the fourth quarter of 2027, so ongoing development and launch costs could eventually require additional funding and dilute shareholders. (U.S. Securities and Exchange Commission, Alumis)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
Alumis Inc. Financial Performance
Revenues and expenses
Alumis Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alumis Inc. News
AllArticlesVideos
Funds containing Alumis Inc.
Fund name | Fund size | $ALMS weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.06% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.06% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.06% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.